A Clinical Proteomic Tumor Analysis Consortium (CPTAC), with grants from the National Cancer Institute, has been formed between Washington University School of Medicine in St. Louis, the University of North Carolina at Chapel Hill, Johns Hopkins University, Vanderbilt University, Pacific Northwest National Laboratory, and Boise State University. Such research could hasten the discovery of the molecular basis of cancer using quantitative proteomic technologies and workflows.
The purpose is to obtain data about proteins in the blood from genetic abnormalities, eventually to be used for cancer screening, diagnosis, and treatment. Extracting functional information about proteins from a massive catalog of genetic information with screens that check for DNA differences between normal cells and cancer cells might allow for early detection, diagnosis, and treatment of cancer. A major goal is to allow researchers doing cancer-related protein studies to share data and methodologies to compare and analyze work with members of the CPTAC network.
For more information on CPTAC, visit http://proteomics.cancer.gov.
To sign up for our newsletter or print publications, please enter your contact information below.
